|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
Amgen Valuation Now Excludes Potential Repatha Revenues [February 13, 2016]
FDA Approves Imlygic (T-vec) for Melanoma [October 27, 2015]
FDA Approves Repatha [Amgen press release August 27, 2015]
Why Amgen is a Biotechnology Portfolio Cornerstone [March 10, 2015 at Seeking Alpha]
2016 |
|||
04/28/2016 |
0727/2016 |
||
2015 |
|||
04/21/2015 |
07/30/2015 |
10/28/2015 |
01/28/2016 |
2014 |
|||
4/22/2014 |
07/29/2014 |
10/27/2014 |
01/27/2015 |
2013 |
|||
Not available |
|||
07/30/2013 |
10/22/2013 |
01/28/2014 |
|
Amgen 2014 Business Review Notes October 28, 2014
Amgen initial purchase March 24, 2014
Amgen with Onyx Pharmaceuticals: Long Term Analysis September 4, 2013
Amgen Valuation [blog 12/3/2007]
I did not follow Amgen closely between the end of 2008 and mid-2013. I did own Onyx Pharmaceuticals during most of that time.
2008 |
|||
 |
|
|
|
Q3 2008 |
Q2 2008 |
Q1 2008 |
Q4 2007 |
10/22/2008 |
07/28/2008 |
04/24/2008 |
1/24/2008 |
2007 |
|||
|
|
|
|
10/24/2007 |
07/26/2007 |
4/23/2007 |
|
Q3 2007 |
Q2 2007 |
Q1 2007 |
|
Amgen is a biotechnology therapeutics company selling a variety of drugs, notably Arenesp, Epogen and Enbrel.
Amgen Web site:
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but its possible. Before making or terminating an investment you should always verify any factual basis of your decision.